Nursing care
Filgrastim: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated September 2026
Short answer
Filgrastim is a granulocyte colony-stimulating factor given after chemotherapy, not during it, to stimulate bone marrow production of neutrophils and shorten the period of neutropenia. Nurses monitor the absolute neutrophil count and watch for bone pain, the drug's most common side effect.
What it does and why it is prescribed
Filgrastim, sold as Neupogen, is a recombinant form of granulocyte colony-stimulating factor, or G-CSF, a naturally occurring hormone that signals bone marrow to produce and release neutrophils. It works on the marrow directly, accelerating neutrophil production rather than acting on cells already in circulation.
It is prescribed to shorten the duration of chemotherapy-induced neutropenia and reduce the risk of febrile neutropenia and infection. It is also used to mobilise stem cells before a bone marrow or peripheral stem cell transplant, and in patients with chronic severe neutropenia unrelated to cancer treatment. The key detail is timing: filgrastim is given after a chemotherapy cycle, once the marrow-suppressive drugs have cleared, not concurrently with them.
Nursing considerations before giving it
Confirm the chemotherapy cycle has actually finished, since filgrastim given too soon after chemotherapy, or during it, can stimulate rapidly dividing marrow cells at the same moment they are being destroyed by cytotoxic drugs, worsening the outcome rather than helping it. Most protocols specify starting filgrastim no sooner than 24 hours after the last chemotherapy dose.
Check a baseline complete blood count with differential before the first dose, so the absolute neutrophil count trend can be interpreted against a starting point. Review the patient's platelet count too, since filgrastim can cause mild thrombocytopenia in some regimens. Verify the injection site if given subcutaneously, rotating sites as with other subcutaneous injections, and check for any known hypersensitivity to E. coli-derived proteins, since filgrastim is produced in this way.
What to monitor
The absolute neutrophil count is the central monitoring parameter and is checked regularly through the course of treatment, typically two to three times a week, to track recovery and guide when the drug can be stopped. Filgrastim is usually continued until the ANC has recovered to a specified threshold, not for a fixed number of days.
Monitor for bone pain, which is the most frequently reported effect and reflects the marrow's rapid activity. Watch also for signs of an enlarged spleen, which can occur with prolonged use and occasionally presents as left upper quadrant or shoulder-tip pain, and monitor for any signs of acute respiratory distress, which is rare but has been reported. Uric acid can rise as cell turnover increases, so this is checked in some patients as well.
Side effects versus adverse effects
Bone pain is the expected, common side effect of filgrastim, caused by the rapid expansion of bone marrow activity, and it is usually managed with a non-opioid analgesic such as acetaminophen rather than treated as a reason to stop the drug. Low-grade fever, headache, and injection site reactions are also common and generally mild.
Adverse effects are less common but more serious: splenic rupture, though rare, is a recognised risk with prolonged use and presents as severe left upper abdominal or shoulder pain requiring urgent evaluation. Acute respiratory distress syndrome has been reported rarely, presenting as fever, lung infiltrates, and respiratory distress. Severe allergic reaction is also possible, as with any protein-based biologic.
What to hold for and when to call
Call the provider for severe or worsening left upper quadrant or shoulder-tip pain, which could indicate splenic enlargement or rupture and needs prompt evaluation rather than routine pain management. Report any new respiratory distress, since this may signal the rare but serious pulmonary reaction associated with the drug.
Hold the dose and notify the provider if a scheduled dose falls within 24 hours of the next chemotherapy cycle, since the two should not overlap. Bone pain that is not controlled with standard analgesia, or any sign of an allergic reaction such as rash, swelling, or difficulty breathing, should also be reported before continuing treatment.
Patient teaching
Explain the timing clearly: this injection is given after chemotherapy has finished, to help the bone marrow recover, not as part of the chemotherapy itself. Patients sometimes confuse the two and understanding the sequence reduces anxiety about receiving another injection so soon after treatment.
Teach patients that bone pain, often described as a deep ache in the long bones, pelvis, or sternum, is common and usually manageable with acetaminophen, and that it reflects the drug working rather than a complication. Show patients or caregivers correct subcutaneous injection technique and site rotation if they will be self-administering doses at home. Tell them to report severe abdominal or shoulder pain, breathing difficulty, fever, or signs of infection immediately, and confirm they know which clinic number to call outside office hours.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
Is filgrastim given during chemotherapy or after it?
After. Filgrastim is started once a chemotherapy cycle has cleared, usually no sooner than 24 hours after the last dose, because giving it during chemotherapy can worsen marrow suppression instead of helping recovery.
What is the most common side effect of filgrastim?
Bone pain, caused by rapid marrow activity as neutrophil production ramps up. It is usually managed with acetaminophen and is not typically a reason to stop treatment.
What lab value is used to monitor filgrastim therapy?
The absolute neutrophil count, checked regularly, usually two to three times a week, to track recovery. Filgrastim is generally continued until the ANC reaches a target threshold rather than for a fixed number of days.
What is a serious complication to watch for with filgrastim?
Splenic enlargement or, rarely, rupture, which presents as severe left upper quadrant or shoulder-tip pain and needs urgent evaluation. Rare acute respiratory distress has also been reported and should prompt immediate reporting of any new breathing difficulty.
More on pharmacology
Guides on this